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cases avoided, recurrent venous thromboembolism cases avoided, ICU days avoided and hospital days avoided. A 3% annual discount rate was applied to QALYs. QALYs were the sole benefit measures assessed over patient lifetimes.
Cost data:
The economic analysis included variable costs of ultrasound (radiologist, nursing, consumables and reporting costs), costs of DVT treatment (including drugs and complications) during hospital stay and costs occurring after hospitalisation for patients who were living at home and in long-term care (medications, outpatient appointments, home care and rehabilitation related to venous thromboembolism and critical illness). Most costs related to hospitalisation were derived from the 20 hospitals in Canada, USA and Australia involved in the economic evaluation of the PROTECT study. Long-term costs and other costs not available from the clinical trial were derived from other published sources. Direct and indirect costs were included. Costs were in US dollars ($). The price year was 2010. Costs were discounted at an annual rate of 3%.
Analysis of uncertainty:
One-way sensitivity analyses were performed for all inputs of the model using published confidence intervals (CIs) or ranges of values defined by the authors. Alternative thromboprophylaxis strategies were considered in alternative scenarios. A probabilistic sensitivity analysis was carried out using a Monte Carlo simulation for 10,000 iterations and conventional probabilistic distributions for model inputs. Cost-effectiveness acceptability curves were depicted.
Results
In the lifetime analysis, screening increased lifetime costs compared with case finding ($185,703,084 versus $185,510,890 per 1,000 patients) and improved quality-adjusted survival by 0.92 QALYs per 1,000 patients. The incremental cost per QALY gained with screening was $209,093 (far above the conventional cost-effectiveness threshold of $50,000 per QALY). When only duration of hospitalisation was considered, the screening strategy was dominated using ICU days avoided and major bleeding episodes as outcome measures. Cost per DVT detected was $3,823, cost per venous thromboembolism avoided was $19,139 and per pulmonary embolism avoided was $71,995.
Sensitivity analysis showed that base case results were sensitive to variations in the cost of screening ultrasound and the probability of proximal DVT: the incremental cost per QALY was less than $50,000 when the probability of proximal DVT exceeded 11% per week or when screening ultrasound cost less than $49. In the probabilistic analysis, screening cost was more than the threshold of $50,000 per QALY in 85% of the simulations.
The hypothetical programme to improve thromboprophylaxis use was cost-effective with an incremental cost per QALY of $22,749 assuming no additional intervention cost and $27,953 assuming a cost of $100 per patient additional intervention cost.
